231 related articles for article (PubMed ID: 36918752)
1. Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study.
Iannone LF; Burgalassi A; Vigani G; Tabasso G; De Cesaris F; Chiarugi A; Geppetti P
Cephalalgia; 2023 Apr; 43(4):3331024231160519. PubMed ID: 36918752
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
3. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study.
Overeem LH; Lange KS; Fitzek MP; Siebert A; Steinicke M; Triller P; Hong JB; Reuter U; Raffaelli B
Front Neurol; 2023; 14():1154420. PubMed ID: 37034092
[TBL] [Abstract][Full Text] [Related]
5. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
[TBL] [Abstract][Full Text] [Related]
6. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
[TBL] [Abstract][Full Text] [Related]
7. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
[TBL] [Abstract][Full Text] [Related]
8. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial.
De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C
J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947
[TBL] [Abstract][Full Text] [Related]
9. Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study.
Braca S; Miele A; Stornaiuolo A; Cretella G; De Simone R; Russo CV
Neurol Sci; 2024 Apr; 45(4):1655-1660. PubMed ID: 38091211
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study.
Straube A; Broessner G; Gaul C; Hamann X; Hipp J; Kraya T; Neeb L
J Headache Pain; 2023 May; 24(1):59. PubMed ID: 37221478
[TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
[TBL] [Abstract][Full Text] [Related]
12. Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
Eur J Neurol; 2022 May; 29(5):1505-1513. PubMed ID: 35098620
[TBL] [Abstract][Full Text] [Related]
13. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
[TBL] [Abstract][Full Text] [Related]
14. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
Curone M; Tullo V; Didier HA; Bussone G
Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis.
Lambru G; Caponnetto V; Hill B; Ratti S; Sacco S; Murphy M; Briscoe J; Andreou AP
Neurotherapeutics; 2023 Sep; 20(5):1284-1293. PubMed ID: 37430146
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
[TBL] [Abstract][Full Text] [Related]
18. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
[TBL] [Abstract][Full Text] [Related]
19. Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a real-world community cohort of persons living with migraine: A retrospective clinical and genetic study.
Chase BA; Semenov I; Rubin S; Meyers S; Mark A; Makhlouf T; Chirayil TT; Maraganore D; Wei J; Zheng SL; Xu J; Epshteyn A; Pham A; Frigerio R; Markopoulou K
Headache; 2024 Jan; 64(1):68-92. PubMed ID: 38071464
[TBL] [Abstract][Full Text] [Related]
20. Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.
Kang SA; Govindarajan R
Muscle Nerve; 2021 Apr; 63(4):563-567. PubMed ID: 33347632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
